RxDoctor Payments Data

Mitesh Bhalala, MD

Gastroenterology · Taunton, MANPI 1639497514

Payments from drug & device makers

$8,374in general payments, 2019–2025

Across 23 payments — averaging $364.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Johnson & Johnson$179
  • Novo Nordisk$82
  • Sanofi$62
  • QOL Medical, LLC$49
  • Phathom Pharmaceuticals, Inc.$47
  • plus $132 from 6 others

What the payments were for

  • Food & beverage$63498%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,374 in reported general payments places this provider in the 75th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$95,884
Medicare patients
430
Services billed
661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab32$915,469
Humira(Cf) PenAdalimumab13$87,690
LinzessLinaclotide71$55,432
TrulancePlecanatide22$18,210
CreonLipase/Protease/Amylase13$9,884
Mesalamine27$9,549
Budesonide EcBudesonide12$7,268
Omeprazole262$4,179
Sucralfate37$3,437
Esomeprazole Magnesium17$3,368
Pantoprazole Sodium214$3,202
Lubiprostone18$2,813
Tenofovir Disoproxil Fumarate21$1,442
Dicyclomine Hcl43$1,102
LoperamideLoperamide Hcl21$959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$179$915,46932 claims
AbbVieLinzess, Creon$7,824$65,31784 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Taunton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →